Scientific article
Open access

The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases

Published inArthritis research & therapy, vol. 11, no. 3, 230
Publication date2009

A better understanding of cytokine biology over the last two decades has allowed the successful development of cytokine inhibitors against tumour necrosis factor and interleukin (IL)-1 and IL-6. The introduction of these therapies should be considered a breakthrough in the management of several rheumatic diseases. However, many patients will exhibit no or only partial response to these therapies, thus emphasising the importance of exploring other therapeutic strategies. In this article, we review the most recent information on novel cytokines that are often members of previously described cytokine families such as the IL-1 superfamily (IL-18 and IL-33), the IL-12 superfamily (IL-27 and IL-35), the IL-2 superfamily (IL-15 and IL-21), and IL-17. Several data derived from experimental models and clinical samples indicate that some of these cytokines contribute to the pathophysiology of arthritis and other inflammatory diseases. Targeting of some of these cytokines has already been tested in clinical trials with interesting results.

Citation (ISO format)
GABAY, Cem, MCINNES, Iain B. The biological and clinical importance of the “new generation” cytokines in rheumatic diseases. In: Arthritis research & therapy, 2009, vol. 11, n° 3, p. 230. doi: 10.1186/ar2680
Main files (1)
Article (Published version)
ISSN of the journal1478-6354

Technical informations

Creation03/02/2010 3:15:00 PM
First validation03/02/2010 3:15:00 PM
Update time03/14/2023 3:24:32 PM
Status update03/14/2023 3:24:32 PM
Last indexation02/12/2024 11:15:33 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack